Table 1.
Baseline characteristics of patients (N=138)
| Localized RCC (N=107) |
De novo mRCC (N=31) |
Total (N=138) |
||||
| n | % | n | % | n | % | |
| Gender | ||||||
| Female | 43 | 40 | 14 | 45 | 57 | 41 |
| Male | 64 | 60 | 17 | 55 | 81 | 59 |
| Histology | ||||||
| ccRCC | 78 | 73 | 25 | 81 | 103 | 75 |
| nccRCC | 28 | 26 | 5 | 16 | 33 | 24 |
| Chromophobe | 14 | 13 | . | . | 14 | 10 |
| Papillary not subtyped | 6 | 6 | 1 | 3 | 7 | 5 |
| Papillary type 1 | 4 | 4 | 1 | 3 | 5 | 4 |
| Papillary type 2 | 3 | 3 | 1 | 3 | 4 | 3 |
| RCC unclassified | 1 | 1 | 2 | 7 | 3 | 2 |
| Unknown | 1 | 1 | 1 | 3 | 2 | 1 |
| Pathological T stage | ||||||
| T1 | 58 | 54 | 2 | 6 | 60 | 44 |
| T2 | 21 | 20 | 7 | 23 | 28 | 20 |
| T3 | 21 | 20 | 21 | 68 | 42 | 30 |
| T4 | 3 | 3 | 1 | 3 | 4 | 3 |
| Unknown | 4 | 4 | . | . | 4 | 3 |
| Pathological N stage | ||||||
| N0 | 33 | 31 | 11 | 36 | 44 | 32 |
| N1 | 8 | 8 | 6 | 19 | 14 | 10 |
| Nx | 62 | 58 | 14 | 45 | 76 | 55 |
| Unknown | 4 | 4 | . | . | 4 | 3 |
| AJCC stage | ||||||
| I | 57 | 53 | . | . | 57 | 41 |
| II | 19 | 18 | . | . | 19 | 14 |
| III (T3 or N1) | 26 | 24 | . | . | 26 | 19 |
| IV (T4 or M1) | 3 | 3 | 31 | 100 | 34 | 25 |
| Unknown | 2 | 2 | . | . | 2 | 1 |
| Fuhrman grade | ||||||
| G1 | 7 | 7 | . | . | 7 | 5 |
| G2 | 59 | 55 | 9 | 29 | 68 | 49 |
| G3 | 26 | 24 | 12 | 39 | 38 | 28 |
| G4 | 13 | 12 | 9 | 29 | 22 | 16 |
| Unknown | 2 | 2 | 1 | 3 | 3 | 2 |
| Sarcomatoid features | ||||||
| No | 100 | 94 | 24 | 77 | 124 | 90 |
| Yes | 4 | 4 | 6 | 19 | 10 | 7 |
| Unknown | 3 | 3 | 1 | 3 | 4 | 3 |
| Adjuvant therapy | ||||||
| No | 103 | 96 | 31 | 100 | 134 | 97 |
| Yes | 3 | 3 | . | . | 3 | 2 |
| Unknown | 1 | 1 | . | . | 1 | 1 |
AJCC, American Joint Committee on Cancer; ccRCC, clear cell renal cell carcinoma; mRCC, metastatic renal cell carcinoma; nccRCC, non-clear cell renal cell carcinoma; RCC, renal cell carcinoma.